MAP2K1 activant la mutation (MEK1)
Vue déterministe de l'entité source de la LJAM. L'autorité clinique demeure avec les ID de la source cités et l'état d'approbation de l ́examinateur.
| ID | BIO-MAP2K1 |
|---|---|
| Type | Biomarqueur |
| Alias | MAP2K1 / mutation MEK1Активуюча мутація MAP2K1 (MEK1) |
| État | reviewed 2026-05-04 | pending_clinical_signoff |
| Maladies | DIS-GLIOMA-LOW-GRADE DIS-HCL |
| Sources | SRC-EANO-LGG-2024 SRC-NCCN-CNS-2025 |
Données biomarqueurs
| Type de biomarqueur | gene_mutation |
|---|---|
| Détails de la mutation | {"exon": "2, 3 (domaine kinase)", "functional_impact":"activation", "gene": «MAP2K1», "variant_type": „missense activation"} |
| Mesure | MéthodePanneaux NGS de tumeurs; variantes clés: K57E (~30% de HCL-V), Q56P, E203K, F53L, D67N |
| Recherche de la faisabilité | {"gene": "MAP2K1", "variant": "activating_mutation"} |
| Biomarqueurs connexes | BIO-BRAF-V600E |
Notes
MAP2K1 (MEK1) is a dual-specificity kinase directly downstream of BRAF and upstream of ERK1/2. Activating mutations constitute an alternative mechanism of MAPK pathway activation in tumors that lack BRAF mutations. Key clinical contexts: (1) Hairy cell leukemia variant (HCL-V): MAP2K1 K57E present in ~40–50% of HCL-V cases (which are BRAF V600E-negative by definition). Cobimetinib (MEK inhibitor) shows activity in MAP2K1-mutant HCL-V in small series; no FDA approval but NCCN 2B evidence. (2) Low-grade glioma (LGG): MAP2K1 mutations are one of the MAPK pathway alterations (~5–10% of BRAF-fusion-negative LGGs). Trametinib (MEK inhibitor) shows activity in pediatric LGG with MAPK pathway alterations per FIREFLY-1 trial (binimetinib/trametinib). (3) Melanoma: MAP2K1 mutations occur in ~5–8% as secondary resistance to BRAF inhibitors; MEK inhibitors still active but combination needed. (4) Histiocytic disorders (ECD, LCH): MAP2K1 mutations as alternative to BRAF V600E. Do not confuse MEK inhibitors approved for BRAF V600E indications — those approvals are as adjuncts to BRAF inhibitors (vemurafenib + cobimetinib; dabrafenib + trametinib) and are not driven by MAP2K1 mutation status.
Utilisé par
Pertinence thérapeutique
BMA-MAP2K1-HCL- La variante de la leucémie des cellules poilues (HCL-V) est un lymphome rare des cellules B de la rate (~10% des cas de HCL)...BMA-MAP2K1-LGG- L'activation de la voie MAPK est le signe distinctif du gliome pédiatrique de faible grade (pLGG) et de l...